ONCOWASH + Nystatin
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
ONCOWASH | SUSPENSION, ORAL | diphenhydramine elixir/viscous lidocaine 2%/Maalox | ||||
ONCOWASH + Nystatin | SUSPENSION, ORAL | diphenhydramine elixir/viscous lidocaine 2%/Maalox/Nystatin (240 mL) | ||||
ONCOWASH + Nystatin w/o Lidocaine | SUSPENSION, ORAL | diphenhydramine elixir/Maalox/Nystatin (180 mL) | ||||
ONCOWASH w/o Lidocaine | SUSPENSION, ORAL | diphenhydramine elixir/Maalox (120 mL) |
ONCOWASH contains a 1:1:1 formulation of: diphenhydrAMINE elixir 12.5 mg/5 mL (60 mL), viscous lidocaine 2% (60 mL), and MAALOX (60 mL).
FIRST Mouthwash BLM Compounding Kit may be utilized for standardized ONCOWASH formulation.
Variations to the standardized formulation are:
*Recommended formulations in pediatric patients < 3 years old due to inability to swish & spit.
MAALOX component may contain simethicone.
Reviewed: 25 March 2015
Updated: 24 Sept 2019 (Formula Update), March 2022